A coalition of 20 attorneys general has initiated pressure on the American Medical Association (AMA) to explain its support for the use of puberty blockers in children, questioning the consistency of the AMA's positions. This coalition, led by Alabama Attorney General Steve Marshall, commended the AMA for agreeing that gender-related surgeries should be postponed until adulthood due to insufficient evidence. However, they highlighted that the evidence supporting puberty blockers is equally weak, demanding an alignment in the AMA's stance regarding treatments for gender dysphoria in minors.

The letter emphasizes that the same lack of clear evidence, which the AMA acknowledged regarding surgeries, equally applies to puberty blockers and cross-sex hormones used in treating minors with gender dysphoria. The attorneys argue that the AMA's continued support for these medical interventions is concerning, suggesting that the quality of evidence for such treatments is either low or very low, similar to that associated with surgical procedures. This inconsistency raises questions about the AMA's credibility in making public health recommendations.

The implications of this pressure campaign extend beyond legal discussions, as it taps into broader societal debates over the treatment of transgender minors. As states increasingly scrutinize medical practices related to gender identity, the outcome of this push could influence future policies and the accessibility of medical treatments for young people experiencing gender dysphoria. A reevaluation of medical guidelines in light of these challenges may be necessary, reflecting the dynamic nature of public health discourse in the U.S.